We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Combined With Infrared Imaging Automatically Classifies Tumors

By LabMedica International staff writers
Posted on 15 Feb 2023

In recent years, there has been a massive advancement in the available treatments for colon cancer. More...

To ensure these therapies, such as immunotherapies, are effective, it is important to accurately diagnose the individual patient to provide specifically tailored treatment. Now, researchers have paired artificial intelligence (AI) with infrared (IR) imaging to develop an automated and precise method for diagnosing colon cancer and tailoring treatments to the patient. This label-free and automated technique complements existing methods for analyzing tissue samples.

Over the course of the past several years, a research team at the Centre for Protein Diagnostics (PRODI) at Ruhr University Bochum (Bochum, Germany) has been working on creating a new digital imaging method known as label-free IR imaging. This method measures the genomic and proteomic composition of the examined tissue, providing molecular information based on the infrared spectra. The information is then decoded using AI and displayed as false-color images utilizing image analysis methods from the field of deep learning.

The PRODI team successfully demonstrated that using deep neural networks, it was possible to effectively determine the microsatellite status, a prognostically and therapeutically relevant parameter, in colon cancer. In this process, the tissue sample passes through a standardized, user-independent, automated process and allows for spatially resolved differential classification of the tumor within an hour. On the other hand, classical diagnostics is used to determine the microsatellite status either through complex immunostaining of various proteins or via DNA analysis.

The ever-improving therapy options have made fast and uncomplicated determination of such biomarkers extremely important. Based on IR microscopic data, the researchers modified, optimized, and trained neuronal networks to establish label-free diagnostics. In contrast to immunostaining, the new approach does not need dyes and is much faster than DNA analysis.

“We were able to show that the accuracy of IR imaging for determining microsatellite status comes close to the most common method used in the clinic, immunostaining,” said PhD student Stephanie Schörner.

Related Links:
Ruhr University Bochum 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Immunofluorescence image of reactive astrocytes (red) in the area surrounding sEcad-high cancer cells (blue, center) (Photo courtesy of Debeb Laboratory)

Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis

Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.